{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-083183","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2022-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.816696+00:00","generated_at":"2026-06-24T08:06:32.797195+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cognition Therapeutics CFO James O'Brien departs; Andrew Einhorn named interim CFO","bullets":["CFO James O'Brien to leave effective August 12, 2022; departure not due to any disagreement with company or auditors.","O'Brien eligible for severance: 9 months base salary and health benefits, contingent on release and restrictive covenants.","Andrew Einhorn appointed Interim CFO effective August 12, via consulting agreement with Danforth Advisors.","Einhorn previously CFO of RVL Pharmaceuticals and Edge Therapeutics; company will search for permanent CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-083183","json":"https://secwatch.observer/filing/0001104659-22-083183.json","markdown":"https://secwatch.observer/filing/0001104659-22-083183.md","text":"https://secwatch.observer/filing/0001104659-22-083183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465922083183/0001104659-22-083183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465922083183/tm2221873d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T08:06:32.797195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8f96158715","claim":"Andrew Einhorn was appointed as Interim Chief Financial Officer at COGNITION THERAPEUTICS INC.","evidence_excerpt":"the board of directors of the Company appointed Andrew Einhorn as Interim Chief Financial Officer, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465922083183/0001104659-22-083183-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"fba35c2872","claim":"James O'Brien departed as Chief Financial Officer at COGNITION THERAPEUTICS INC.","evidence_excerpt":"the Company determined that James O’Brien, the Company’s Chief Financial Officer, will be leaving the Company as of August 12, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465922083183/0001104659-22-083183-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}